U.S. halts distribution of Eli Lilly’s coronavirus antibody treatment bamlanivimab as a monotherapy

America, Coronavirus, Health, Science, Treatment, USA, Variants

The U.S. government has halted distribution of Eli Lilly’s COVID-19 antibody treatment bamlanivimab (LY-CoV555) as a monotherapy just four months after it received FDA emergency use authorization, citing a sustained increase in variants of SARS-CoV-2 that are resistant to the monotherapy.

In announcing the halt this week, the U.S. Office of the Assistant Secretary for Preparedness and Response (ASPR) said it will continue to distribute bamlanivimab in combination with etesevimab (LY-CoV16 or JS-16), another Lilly antibody. The combination won FDA authorization for emergency use last month.

Genengnews.com report


Image by Darko Stojanovic from Pixabay

** This post was originally published on March 26, 2021 **